NCT02689843View on ClinicalTrials.gov

Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

November 30, 2018

Study Completion Date

December 30, 2018

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Cyproterone compound + Spironolactone

Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily

DRUG

Metformin

Metformin 500mg three times daily

DRUG

Pioglitazone

Pioglitazone 30mg once daily

Trial Locations (1)

Unknown

Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz

All Listed Sponsors
lead

Shiraz University of Medical Sciences

OTHER

NCT02689843 - Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS | Biotech Hunter | Biotech Hunter